广生堂上涨5.5%，报121.8元/股

Group 1 - The core viewpoint of the article highlights the recent stock performance of Guangshengtang, which saw a 5.5% increase, reaching a price of 121.8 yuan per share, with a trading volume of 597 million yuan and a turnover rate of 3.68%, resulting in a total market capitalization of 19.399 billion yuan [1] - Guangshengtang Pharmaceutical Co., Ltd. is located in Fujian Province and focuses on antiviral and liver health sectors, possessing five major clinical preferred drugs for hepatitis B virus, with a high market share for its main products [1] - The company has been actively expanding into cardiovascular, male health, and high-end difficult-to-generate drug areas, successfully obtaining approvals for multiple innovative drugs to achieve a leading position in the antiviral drug sector [1] Group 2 - As of March 31, Guangshengtang had 14,000 shareholders, with an average of 9,763 circulating shares per person [1] - For the first quarter of 2025, Guangshengtang reported an operating income of 97.608 million yuan, a year-on-year decrease of 18.69%, and a net profit attributable to shareholders of -28.489 million yuan, reflecting a significant year-on-year decline of 94.56% [1]